New CME Course: Evolving Guidelines and Targets – When and How to Use the PCSK9 Inhibitors

Course Launch Announcement: Evolving Guidelines and Targets – When and How to Use the PCSK9 Inhibitors

Target audience: The intended audience for the activity is Primary Care Physicians; Nurse Practitioners; Physician Assistants

In this unique, interactive program, Dr. Christopher Cannon, an internationally recognized expert in cardiovascular medicine, reviews the key clinical trial data for the PCSK9 inhibitors and discusses their potential role in clinical practice. In a live meeting (archived for learners unable to attend), Dr. Cannon will directly address learners’ questions and issues in the use of new lipid-lowering therapies.
The following topics will be discussed:
  • Whom to treat: New guidelines and lipid targets for specific patient groups
  • How to treat: Selecting the appropriate intensity of statin therapy
  • Achieving targets: Managing insufficient statin response or statin intolerance
  • New agents: When and how to use new agents, such as the PCSK9 inhibitors

This activity, Evolving Guidelines and Targets: When and How to Use the PCSK9 Inhibitors, offers 1.50 AMA PRA Category 1 Credit(s)™ and is available at: http://realcme.com/cms/node/712741.